Mesoblast Ltd Files Quarterly Report
Ticker: MEOBF · Form: 6-K · Filed: Nov 1, 2024 · CIK: 1345099
| Field | Detail |
|---|---|
| Company | Mesoblast LTD (MEOBF) |
| Form Type | 6-K |
| Filed Date | Nov 1, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: quarterly-report, cash-flow, biotech
TL;DR
MESO filed its Q3 2024 Appendix 4C, showing cash flow and operational updates.
AI Summary
Mesoblast Limited filed a quarterly report (Appendix 4C) with the Australian Securities Exchange on October 31, 2024, detailing its activities for the quarter ending September 30, 2024. The report covers cash flows and operational updates for entities admitted on the basis of commitments.
Why It Matters
This filing provides investors with an update on Mesoblast's financial position and operational progress, crucial for assessing the company's ongoing development and cash burn.
Risk Assessment
Risk Level: medium — As a biotech company, Mesoblast faces inherent risks related to clinical trial success, regulatory approvals, and market adoption, which are often reflected in quarterly reports.
Key Players & Entities
- Mesoblast Limited (company) — Registrant
- Silviu Itescu (person) — Chief Executive Officer and Executive Director
- October 31, 2024 (date) — Filing date of Appendix 4C
- September 30, 2024 (date) — End of reporting quarter
FAQ
What specific financial information is detailed in the Appendix 4C filing?
The Appendix 4C filing details cash flows for the quarter, including cash used in operating activities, investing activities, and financing activities, as well as cash and cash equivalents at the end of the period.
What is the primary purpose of the Appendix 4C filing for Mesoblast?
The Appendix 4C is a quarterly report for entities admitted on the basis of commitments, providing an update on their cash position and operational activities.
When was the Appendix 4C report filed with the Australian Securities Exchange?
The Appendix 4C report was filed with the Australian Securities Exchange on October 31, 2024.
What period does the Appendix 4C report cover?
The report covers the quarter ending September 30, 2024.
Who is identified as the Chief Executive Officer and Executive Director of Mesoblast Limited?
Silviu Itescu is identified as the Chief Executive Officer and Executive Director of Mesoblast Limited.
Filing Stats: 229 words · 1 min read · ~1 pages · Grade level 18.1 · Accepted 2024-10-31 19:51:26
Filing Documents
- a2024-11x01activitystateme.htm (6-K) — 20KB
- exhibit991.htm (EX-99.1) — 33KB
- exhibit991001.jpg (GRAPHIC) — 220KB
- exhibit991002.jpg (GRAPHIC) — 267KB
- exhibit991003.jpg (GRAPHIC) — 262KB
- exhibit991004.jpg (GRAPHIC) — 248KB
- exhibit991005.jpg (GRAPHIC) — 118KB
- exhibit991006.jpg (GRAPHIC) — 120KB
- exhibit991007.jpg (GRAPHIC) — 174KB
- exhibit991008.jpg (GRAPHIC) — 229KB
- exhibit991009.jpg (GRAPHIC) — 211KB
- exhibit991010.jpg (GRAPHIC) — 139KB
- 0001345099-24-000074.txt ( ) — 2794KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized. Mesoblast Limited s Paul Hughes Paul Hughes Company Secretary Dated November 1, 2024 INDEX TO EXHIBITS Item 99.1 Appendix 4C of Mesoblast Ltd, dated October 31 , 2024.